Press release
Hemochromatosis/Iron Overload Therapeutics 2018 - Pipeline Analysis, Clinical Trials and Developments
Explore report sample at: https://www.psmarketresearch.com/market-analysis/iron-overload-therapeutics-pipeline/report-sample
As of now, there are three marketed iron chelator drugs available for the treatment of hemochromatosis namely; Deferasirox, Deferoxamine and Deferiprone. Limited competition gives companies investing in the hemochromatosis therapeutics pipeline an opportunity to gain market share. Thus, driving the growth of the hemochromatosis therapeutics pipeline.
Hemochromatosis most of the times develops as a hereditary disease. Therefore, it has been observed that the companies are developing drug candidates that suppresses the expression of genes. For instance, ALN-TMP by Alnylam Pharmaceuticals Inc. is under the Pre-Clinical phase of development for the treatment of hemochromatosis. The drug candidate is a Tmprss6 gene suppressor being developed using RNA interference (RNAi) technology.
Browse report at: https://www.psmarketresearch.com/market-analysis/iron-overload-therapeutics-pipeline
Some of the key players involved in the development of hemochromatosis therapeutics include La Jolla Pharmaceutical Company, Silence Therapeutics plc, and Shire Plc.
About P&S Intelligence
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hemochromatosis/Iron Overload Therapeutics 2018 - Pipeline Analysis, Clinical Trials and Developments here
News-ID: 1215672 • Views: 480
More Releases from P&S Intelligence - Pharmaceuticals
Cyclin-Dependent Kinase Inhibitors Therapeutics Key Players Analysis - Merck, El …
The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development.
CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation.
Download report sample at: http://bit.ly/2eqiPu5
**Various collaborations for CDK inhibitors drug development
Eli Lilly…
Systemic Lupus Erythematosus Pipeline Analysis - Anthera Pharmaceuticals, Inc., …
The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development.
Explore report sample at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis/report-sample
Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the…
Herpes Simplex Virus Infections Therapeutic - Pipeline Analysis, Clinical Trials …
The study analysed that the Herpes simplex virus infections pipeline comprises of 20 drug candidates in different stages of development.
As per the findings of the research, most of the drug candidates are being developed to be administered by oral route.
Explore report sample at: https://www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis/report-sample
Many technologies are being developed that offer promising innovative treatments which can control the progression of Herpes simplex virus infections. The technologies include, but not limited to,…
Japanese Encephalitis Therapeutics - Pipeline Analysis, Clinical Trials, Patent …
Japanese encephalitis is a viral infection that spreads by mosquito bites. The study analyzed that the Japanese encephalitis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development.
Explore report sample at: https://www.psmarketresearch.com/market-analysis/japanese-encephalitis-therapeutics-pipeline/report-sample
The companies developing drugs for the treatment of Japanese encephalitis are laying more emphasis on the drug candidates to be developed as vaccines, due to the promising results shown by these candidates the in the clinical development.…
More Releases for Hemochromatosis
Hemochromatosis Treatment Market Intelligence Study for Comprehensive Insights
Hemochromatosis is nothing but an unusual accumulation of iron in the parenchymal organs. The over-accumulation of iron leads to a toxic condition in the organs. Hemochromatosis is a very common autosomal rHemochromatosis is also diagnosed by imaging tests which include chest radiography and echocardiography, CT scanning and sometimes MRI may also be helpful in evaluating hepatic iron quantification. Diagnostic endoscopy, skin endoscopy, and liver biopsy can be used to evaluate…
Hemochromatosis-Global Drug Forecast and Market Analysis to 2026
Summary:
ReportsWeb.com published “Hemochromatosis-Global Drug Forecast and Market Analysis to 2026” from its database. The report reviews top companies involved and enlists all trials pertaining to the company. Report provides latest news for the past three months.
Original Content:
While the global T2D market is crowded with inexpensive generics and marked by a pipeline filled with me-too drugs, Publisher expects this market to undergo substantial growth between 2016 and 2026, doubling over the…
Hemochromatosis Treatment Market Trends and Growth Drivers Analysis 2025
Hemochromatosis is nothing but an unusual accumulation of iron in the parenchymal organs. The over-accumulation of iron leads to a toxic condition in the organs. Hemochromatosis is a very common autosomal rHemochromatosis is also diagnosed by imaging tests which include chest radiography and echocardiography, CT scanning and sometimes MRI may also be helpful in evaluating hepatic iron quantification. Diagnostic endoscopy, skin endoscopy, and liver biopsy can be used to evaluate…
Hemochromatosis Treatment Market is Expected to Boost Up by 2025
Hemochromatosis is nothing but an unusual accumulation of iron in the parenchymal organs. The over-accumulation of iron leads to a toxic condition in the organs. Hemochromatosis is a very common autosomal rHemochromatosis is also diagnosed by imaging tests which include chest radiography and echocardiography, CT scanning and sometimes MRI may also be helpful in evaluating hepatic iron quantification. Diagnostic endoscopy, skin endoscopy, and liver biopsy can be used to evaluate…
Hemochromatosis (Genetic Disorders) pipeline Forecast, H1, 2017- Pharmaceutical …
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Hemochromatosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hemochromatosis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Request Free…
Hemochromatosis Pipeline -Therapeutics Review H1 2017
Hemochromatosis - Pipeline Review, H1 2017 report provides comprehensive information on the therapeutics under development for Hemochromatosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved…
